Article
Circulating Tumour DNA in EGFR-Mutant Non-Small-Cell Lung Cancer
1 Jun 2018
Abstract excerpt
The advent of targeted therapy in non-small-cell lung cancer (NSCLC) has made the routine molecular diagnosis of EGFR mutations crucial for optimal patient management. Obtaining tumour tissue for biomarker testing, especially in the setting of re-biopsy, can present many challenges. A potential alternative source of tumour dna is circulating cell-free tumour-derived DNA (CTDNA). Although CTDNA is present in low...
Topics
Join the communities discussing this publication.